XML 38 R22.htm IDEA: XBRL DOCUMENT v3.25.0.1
Income Taxes
12 Months Ended
Dec. 31, 2024
Income Taxes  
Income Taxes

(16) Income Taxes

The components of income tax benefit (provision) are as follows:

Year Ended December 31, 

    

2024

    

2023

    

2022

(In thousands)

Income tax benefit (provision):

Federal

$

39,821

$

36,067

$

17,484

State

15,375

13,691

9,606

Expiration of NOLs and R&D credit

(82,825)

(15,141)

(16,862)

(27,629)

34,617

10,228

Deferred tax valuation allowance

27,629

(34,617)

(10,228)

$

$

$

A reconciliation between the amount of reported income tax and the amount computed using the U.S. statutory rate is as follows:

    

2024

    

2023

    

2022

(In thousands)

Pre-tax loss

$

(157,863)

$

(141,429)

$

(112,325)

Loss at statutory rates

(33,151)

(29,700)

(23,588)

Research and development credits

(7,332)

(5,237)

(3,876)

State taxes

(15,375)

(13,691)

(9,606)

Other

662

(1,130)

11,421

Change in fair value remeasurement of contingent consideration

(1,441)

Expiration of Federal and State NOLs and R&D credits

82,825

15,141

16,862

Change in valuation allowance

(27,629)

34,617

10,228

Income tax (benefit) provision

$

$

$

Deferred tax assets and liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using future expected enacted rates. The principal components of the deferred tax assets and liabilities at December 31, 2024 and 2023 are as follows:

    

December 31, 

    

December 31, 

2024

2023

(In thousands)

Gross deferred tax assets

Net operating loss carryforwards

$

176,816

$

197,618

Tax credit carryforwards

24,718

56,830

Deferred research and development expenses

101,047

82,077

Stock-based compensation

20,940

14,671

Fixed assets

1,033

1,019

Accrued expenses and other

429

398

324,983

352,613

Gross deferred tax liabilities

IPR&D intangibles

(6,840)

(6,840)

Total deferred tax assets and liabilities

318,143

345,773

Valuation allowance

(319,756)

(347,386)

Net deferred tax liability

$

(1,613)

$

(1,613)

The Company has evaluated the positive and negative evidence bearing upon the realizability of its net deferred tax assets and considered its history of losses, ultimately concluding that it is “more likely than not” that the Company will not recognize the benefits of federal, state and foreign deferred tax assets and, as such, has maintained a full valuation allowance on its deferred tax assets.

The net deferred tax liability of $1.6 million at December 31, 2024 and 2023, relates to the temporary differences associated with the IPR&D intangible assets acquired in previous business combinations and are not deductible for tax purposes.

As of December 31, 2024, the Company had federal and state net operating loss carryforwards of $566.0 million and $888.8 million, respectively, which may be available to offset certain future income tax liabilities. State net operating loss carryforwards begin to expire in 2024. The federal net operating loss carryforwards of $566.0 million are from 2005 through 2024 and begin to expire in 2024. As of December 31, 2024, the Company also had federal and state research and development tax credit carryforwards of $19.8 million and $6.3 million, respectively, which may be available to offset future income tax liabilities and begin to expire in 2040 and 2029, respectively.

Utilization of the net operating loss carryforwards and research and credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986, or Section 382, due to ownership changes that occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has performed a study under Internal Revenue Code Section 382 as of June 30, 2024, and concluded that a change in ownership following stock issuances in 2016 and 2020 triggered Section 382 limitations and approximately $758.7 million of federal NOL carryforwards and $48.7 million of federal tax credit carryforwards that were generated through June 30, 2020 will expire unutilized due to Section 382 and 383 limitations. The Company also estimated the amounts of State net operating loss and research and development tax credit carryforwards which will expire unutilized as a result of its annual limitations under Section 382 and has excluded those amounts from the carryforward amounts disclosed above and in the deferred tax assets and liabilities table included in this footnote.

As of December 31, 2024 and 2023, the Company did not have any unrecognized tax benefits.

Massachusetts, New Jersey, New York and Connecticut are the jurisdictions in which the Company primarily operates or has operated and has income tax nexus. The Company is not currently under examination by these or any other jurisdictions for any tax year. Generally, in U.S. federal and state taxing jurisdictions, all years which generated net operating losses and/or tax credit carryforwards remain subject to examination to the extent those carryforwards are utilized in a subsequent period.